<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925639</url>
  </required_header>
  <id_info>
    <org_study_id>CEP/UNIFESP 0728/08</org_study_id>
    <nct_id>NCT00925639</nct_id>
  </id_info>
  <brief_title>Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause</brief_title>
  <official_title>Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoestrogenism, common in menopause, is responsible for systemic and metabolic changes
      affecting women's wellness, favoring hot flashes, urogenital atrophy and bone mass loss.
      Hormone reposition therapy (HRT) with estrogen or estrogen associated to progesterone is
      administered to minimize these effects. Meanwhile, the beneficial effects of HRT are known,
      there is still concern about its adverse effects such as thromboembolic and cardiovascular
      effects, increased risk of breast and endometrial cancer. Thus, there is an increasing
      interest in the development of phytohormonal HRT. The aim of the investigators' study is to
      evaluate the effects of concentrated extract of soy on hypercoagulation markers in menopausal
      women.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of serum DDimer</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Isoflavone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive daily doses of 150 mg of concentrated extract of soy per os</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive daily placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflavone</intervention_name>
    <description>150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.</description>
    <arm_group_label>Isoflavone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starch pill</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 1 year of amenorrhea

          -  45 to 65 years old

          -  without hormone reposition treatment or herbal medications in the 6 months preceding
             the research

        Exclusion Criteria:

          -  history of thromboembolism

          -  history of cardiovascular disease

          -  presence of estrogen dependent neoplasia

          -  presence of abnormal genital bleeding

          -  uncontrolled metabolic diseases

          -  smoking or drinking habits

          -  use of anticoagulants or acetyl salicylic acid
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro A Aidar, M.D., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade Federal de São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Regiane HB Rabelo, MD</last_name>
    <phone>5511-72307128</phone>
    <email>gianehelena@ig.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teresa R Embiruçu, MD</last_name>
    <phone>5511-74513521</phone>
    <email>embirucu2@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ambulatório de Ginecologia Endócrina</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cecília Santos, Nurse</last_name>
      <phone>5511-55496174</phone>
      <email>mc.santos@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Regiane HB Rabelo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.unifesp.br</url>
    <description>Universidade Federal de Sao Paulo's web page</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <last_update_submitted>June 19, 2009</last_update_submitted>
  <last_update_submitted_qc>June 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Regiane Helena Barros Rabelo</name_title>
    <organization>Departamento de Ginecologia da Universidade Federal de São Paulo</organization>
  </responsible_party>
  <keyword>phytoestrogen</keyword>
  <keyword>coagulation</keyword>
  <keyword>menopause</keyword>
  <keyword>ddimer</keyword>
  <keyword>antithrombin</keyword>
  <keyword>hypercoagulation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

